Journal article
Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium
HA Robbins, A Ferreiro-Iglesias, T Waterboer, N Brenner, M Nygard, N Bender, L Schroeder, A Hildesheim, M Pawlita, G D'souza, K Visvanathan, H Langseth, NF Schlecht, LF Tinker, I Agalliu, S Wassertheil-Smoller, E Ness-Jensen, K Hveem, S Grioni, R Kaaks Show all
Journal of Clinical Oncology | Published : 2022
DOI: 10.1200/JCO.21.01785
Abstract
PURPOSESeropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.METHODSWe constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality.RESULTSThe nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10..
View full abstractRelated Projects (1)
Grants
Awarded by State of Maryland